Shifting paradigms in retinopathy of prematurity treatment: The promise and challenges of biosimilars

IF 4.9 2区医学 Q1 OPHTHALMOLOGY

Clinical and Experimental Ophthalmology Pub Date : 2024-12-05 DOI:10.1111/ceo.14460

Robert H. Henderson MD(Res), FRCOphth, Omar Warda MD, MRCS

引用次数: 0

查看原文本刊更多论文

早产儿视网膜病变治疗模式的转变：生物仿制药的前景和挑战。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical and Experimental Ophthalmology 医学-眼科学

CiteScore

7.60

自引率

12.50%

发文量

150

审稿时长

4-8 weeks

期刊介绍： Clinical & Experimental Ophthalmology is the official journal of The Royal Australian and New Zealand College of Ophthalmologists. The journal publishes peer-reviewed original research and reviews dealing with all aspects of clinical practice and research which are international in scope and application. CEO recognises the importance of collaborative research and welcomes papers that have a direct influence on ophthalmic practice but are not unique to ophthalmology.